Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort-Reference-Cited by-同舟云学术

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort

Published:2021-12 Issue: Volume:162 Page:119-127
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Girard Nicolas,Perol Maurice,Simon Gaëtane,Audigier Valette Clarisse,Gervais Radj,Debieuvre Didier,Schott Roland,Quantin Xavier,Coudert Bruno,Lena Hervé,Carton Matthieu,Robain Mathieu,Filleron Thomas,Chouaid Christos

Funder

Pfizer

Meso Scale Diagnostics

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. World Health Organization, Cancer Fact Sheet No. 297, (2017) (http://www.who.int/mediacentre/factsheets/fs297/en/).

2. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003;Yang;Chest,2005

3. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study;Goya;Lung Cancer,2005

4. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer;Eberhardt;Ann. Oncol.,2015

5. Radiotherapy for locally advanced non-small cell lung cancer;Girard;Eur. J. Cancer,2009

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma;Scientific Reports;2023-08-16

2. Treatment of unresectable stage III NSCLC: Real world cohort study and literature review;Cancer Treatment and Research Communications;2023

3. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments;Journal of Thoracic Disease;2022-06